Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth

Core Viewpoint - Vertex Pharmaceuticals (VRTX) is expected to report a year-over-year increase in earnings and revenues for the quarter ended June 2025, with a consensus outlook that will significantly influence its stock price depending on actual results compared to estimates [1][2]. Earnings Expectations - The consensus EPS estimate for Vertex is $4.24 per share, reflecting a year-over-year increase of +133.1% [3]. - Expected revenues for the quarter are $2.89 billion, which is a 9.2% increase from the previous year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 0.31% higher, indicating a positive reassessment by analysts [4]. - Vertex has an Earnings ESP of +1.82%, suggesting analysts have become more optimistic about the company's earnings prospects [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - Vertex currently holds a Zacks Rank of 3, which, along with its positive Earnings ESP, suggests a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Vertex was expected to post earnings of $4.22 per share but actually reported $4.06, resulting in a surprise of -3.79% [13]. - Over the last four quarters, Vertex has only beaten consensus EPS estimates once [14]. Industry Comparison - Regeneron (REGN), another player in the biomedical industry, is expected to report an EPS of $8.03, which represents a year-over-year decline of -30.5% [18]. - Regeneron's revenues are projected to be $3.34 billion, down 5.7% from the previous year, with a recent EPS estimate revision of -6.5% [19].